Compare ADPT & SFBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | SFBS |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.4B |
| IPO Year | 2019 | 2014 |
| Metric | ADPT | SFBS |
|---|---|---|
| Price | $27.73 | $38.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $33.86 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 2.1M | 431.3K |
| Earning Date | 11-04-2026 | 10-19-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | ★ 63.89 | 21.63 |
| EPS | N/A | ★ 2.34 |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $10.85 | $20.23 |
| Revenue Next Year | $21.60 | $8.48 |
| P/E Ratio | ★ N/A | $16.72 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $12.00 | $37.51 |
| 52 Week High | $32.21 | $92.08 |
| Indicator | ADPT | SFBS |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 32.43 |
| Support Level | $24.02 | $37.51 |
| Resistance Level | $29.92 | $43.15 |
| Average True Range (ATR) | 1.71 | 1.11 |
| MACD | -0.09 | -0.13 |
| Stochastic Oscillator | 31.91 | 0.64 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.